A trial of OPC-167832 in combination with Delamanid in drug susceptible tuberculosis patients
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Delamanid (Primary) ; OPC-167832 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 01 Feb 2018 New trial record
- 29 Jan 2018 According to an Otsuka media release, the company received a grant for up to US $10 million from the Bill & Melinda Gates Foundation to advance clinical development of OPC-167832 in combination with delamanid to treat tuberculosis (TB).
- 29 Jan 2018 According to an Otsuka media release, this trial is scheduled to begin in the fourth quarter of 2018.